论文部分内容阅读
目的观察选择性环氧合酶-2(COX-2)抑制剂塞来昔布在体内及体外对肺癌细胞的抑制作用。方法噻唑蓝(MTT)比色法检测肺癌细胞的增殖抑制,流式细胞仪检测塞来昔布处理后肺癌细胞周期变化,通过裸鼠移植瘤实验,比较移植瘤重量检测塞来昔布对肺癌细胞体内抑制作用,TUNEL法染色检测移植瘤癌细胞凋亡。结果塞来昔布对肺癌细胞增殖有抑制作用,且呈剂量依赖关系,IC 50为50 umol/L。塞来昔布可将细胞阻滞在G0/G1期,阻碍G1期细胞进入S期。称量裸鼠移植肿瘤的瘤结节重量,对照组平均瘤重(2.1567±0.9750)g,药物组平均瘤重(0.9783±0.5423)g,两组有显著性差异(P<0.05),抑瘤率为54.64%。TUNEL法移植瘤凋亡细胞染色,对照组凋亡指数(AI)为(1.58±0.61),用药组(9.50±2.51),二组有显著性差异(P<0.05)。结论塞来昔布在体内及体外均对肺癌细胞表现出抑制作用,其将细胞周期阻滞在G1期并诱导肿瘤细胞凋亡可能是抑制肺癌细胞增殖的重要机制。
Objective To observe the inhibitory effect of selective cyclooxygenase-2 (COX-2) inhibitor celecoxib on lung cancer cells in vitro and in vivo. Methods MTT assay was used to detect the proliferation of lung cancer cells. The cell cycle of lung cancer cells was detected by flow cytometry. The effects of celecoxib on the lung cancer In vivo inhibition of cells, TUNEL staining of apoptotic tumor cells. Results Celecoxib inhibited the proliferation of lung cancer cells in a dose-dependent manner with an IC50 of 50 umol / L. Celecoxib blocks cells in the G0 / G1 phase, hindering the G1 phase cells into the S phase. The mean tumor weight (2.1567 ± 0.9750) g in the control group and the average tumor weight in the drug group (0.9783 ± 0.5423) g were significantly higher than those in the control group (P <0.05) The rate was 54.64%. TUNEL staining showed that apoptosis index (AI) was (1.58 ± 0.61) in the control group and (9.50 ± 2.51) in the control group, with significant difference between the two groups (P <0.05). Conclusion Celecoxib inhibits lung cancer cells both in vitro and in vivo. It blocks cell cycle in G1 phase and induces apoptosis of tumor cells, which may be an important mechanism of inhibiting the proliferation of lung cancer cells.